Cooper Companies (COO) Q2 FY26 earnings call

Cooper posted a record quarter on disciplined execution and back-office leverage, but the story is now dominated by two overhangs: an active process to sell CooperSurgical after clearing the embryo-media litigation, and a softening Asia-Pac consumer market that forced a trim to CooperVision's outlook. Management frames the APAC weakness as regional and temporary while pivoting toward stepped-up capital return.